FDA approves new HPV cervical cancer test

The test was approved despite objections from some that the screening had not been adequately tested.

Modern Healthcare: FDA Approves First HPV Test For Primary Cervical-Cancer Screening
The first human papillomavirus DNA test to screen women for cervical cancer was approved Thursday by the U.S. Food and Drug Administration. The stand-alone test can be used to assess whether women need to undergo additional testing and their risk of developing cervical cancer in the future (Rice, 4/24).

The New York Times: Alternative to Pap Test Is Approved By F.D.A.
A committee of outside advisers to the F.D.A. unanimously endorsed the Roche test in a meeting last month. But a coalition of 17 consumer, women's and health groups opposed the approval, arguing that the new screening method had not been adequately tested and could upend a practice that has successfully prevented cervical cancer for decades (Pollack, 4/24).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation